相关实验视频
Updated: Jul 27, 2025

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
Published on: August 29, 2016
转移性前列腺癌的分子向疗法:最近的进展和未来的挑战
Carlo Sorrentino1,2, Emma Di Carlo1,2
1Department of Medicine and Sciences of Aging, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
新型向疗法对转移性前列腺癌具有前景,特别是前列腺特异性膜抗原向的放射性核素疗法和DNA修复抑制剂. 对于其他方法,如抗血管生成和免疫检查点抑制剂,需要进一步的研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 前列腺癌是男性的主要恶性瘤,尽管局部治疗的进展,转移性疾病的预后不佳.
- 转移性割抵抗性前列腺癌 (mCRPC) 提出了重大的治疗挑战.
研究的目的:
- 审查针对mCRPC的新型分子向疗法.
- 讨论新兴前列腺癌治疗方法的有效性和挑战.
- 突出前列腺癌治疗的未来研究方向.
主要方法:
- 对前列腺癌向治疗的相关研究和临床试验的全面审查.
- 分析治疗方法,包括放射性核素疗法,DNA修复抑制剂,抗血管生成和免疫检查点抑制剂.
主要成果:
- 前列腺特异性膜抗原向放射性核素疗法和DNA修复抑制剂在mCRPC中显示出显著的希望,其中包括一些FDA批准的协议.
- 针对瘤新血管化和免疫检查点抑制剂的疗法尚未在mCRPC中显示出明确的临床益处.
结论:
- 向疗法是治疗转移性前列腺癌,特别是mCRPC的前沿前沿.
- 持续的研究和临床试验对于克服挑战和改善晚期前列腺癌患者的治疗结果至关重要.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics